<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Use of granulocyte colony stimulating factors in adult patients with chemotherapy-induced neutropenia and conditions other than acute leukemia, myelodysplastic syndrome, and hematopoietic cell transplantation</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Use of granulocyte colony stimulating factors in adult patients with chemotherapy-induced neutropenia and conditions other than acute leukemia, myelodysplastic syndrome, and hematopoietic cell transplantation</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Use of granulocyte colony stimulating factors in adult patients with chemotherapy-induced neutropenia and conditions other than acute leukemia, myelodysplastic syndrome, and hematopoietic cell transplantation</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard A Larson, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Reed E Drews, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sadhna R Vora, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 19, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H523774176"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Cytotoxic chemotherapy can cause profound and sometimes prolonged neutropenia, which may result in hospitalization for treatment of fever or cause a potentially fatal infection [<a href="#rid1">1,2</a>]. Although profound prolonged neutropenia is most likely in the pre-engraftment phase of hematopoietic cell transplantation (HCT; particularly allogeneic) and in patients undergoing induction therapy for acute leukemia, chemotherapy-related neutropenia can also occur in patients receiving standard-dose chemotherapy for other neoplasms. In an attempt to decrease infectious complications, recombinant human granulocyte colony stimulating factor (G-CSF; <a class="drug drug_general" data-topicid="8446" href="/d/drug information/8446.html" rel="external">filgrastim</a> and pegylated filgrastim) and granulocyte-macrophage colony stimulating factor (GM-CSF; <a class="drug drug_general" data-topicid="9878" href="/d/drug information/9878.html" rel="external">sargramostim</a>) have been used to reduce the duration and degree of neutropenia.</p><p>The role of the G-CSFs in patients receiving standard-dose myelosuppressive chemotherapy for conditions other than acute leukemia or myelodysplastic syndrome (MDS) or in patients undergoing HCT will be reviewed here. The role of G-CSFs in patients with myelodysplastic syndrome, in those undergoing induction chemotherapy for acute leukemia, and in the setting of HCT is addressed elsewhere, as are the potential side effects of CSFs (eg, bone pain, risk of therapy-related myeloid neoplasms). (See  <a class="medical medical_review" href="/d/html/1397.html" rel="external">"Prevention of infections in hematopoietic cell transplant recipients", section on 'Immunomodulation'</a> and  <a class="medical medical_review" href="/d/html/8383.html" rel="external">"Introduction to recombinant hematopoietic growth factors", section on 'Toxicity of colony-stimulating factors'</a> and  <a class="medical medical_review" href="/d/html/3538.html" rel="external">"Hematopoietic support after hematopoietic cell transplantation", section on 'Growth factor support'</a> and  <a class="medical medical_review" href="/d/html/4525.html" rel="external">"Acute myeloid leukemia: Induction therapy in medically fit adults", section on 'Adjunctive care'</a> and  <a class="medical medical_review" href="/d/html/15776.html" rel="external">"Myelodysplastic syndromes/neoplasms (MDS): Management of hematologic complications in lower-risk MDS", section on 'Neutropenia'</a>.)</p><p>An overview of neutropenic fever syndromes; antibacterial, antifungal, and antiviral prophylaxis for patients undergoing myelosuppressive chemotherapy or induction therapy for acute leukemia or HCT; and the management of patients with neutropenic fever are discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/16708.html" rel="external">"Overview of neutropenic fever syndromes"</a> and  <a class="medical medical_review" href="/d/html/1153.html" rel="external">"Prophylaxis of infection during chemotherapy-induced neutropenia in high-risk adults"</a> and  <a class="medical medical_review" href="/d/html/16141.html" rel="external">"Prophylaxis of invasive fungal infections in adults with hematologic malignancies"</a> and  <a class="medical medical_review" href="/d/html/16534.html" rel="external">"Prophylaxis of invasive fungal infections in adult hematopoietic cell transplant recipients"</a> and  <a class="medical medical_review" href="/d/html/1397.html" rel="external">"Prevention of infections in hematopoietic cell transplant recipients"</a> and  <a class="medical medical_review" href="/d/html/13951.html" rel="external">"Treatment and prevention of neutropenic fever syndromes in adult cancer patients at low risk for complications"</a> and  <a class="medical medical_review" href="/d/html/1400.html" rel="external">"Treatment of neutropenic fever syndromes in adults with hematologic malignancies and hematopoietic cell transplant recipients (high-risk patients)"</a> and  <a class="medical medical_review" href="/d/html/4525.html" rel="external">"Acute myeloid leukemia: Induction therapy in medically fit adults", section on 'Adjunctive care'</a>.)</p><p class="headingAnchor" id="H523774183"><span class="h1">DEFINITIONS</span></p><p class="headingAnchor" id="H523774191"><span class="h2">Neutropenia</span><span class="headingEndMark"> — </span>Although definitions are variable from institution to institution, severe neutropenia is defined as an absolute neutrophil count (ANC) of &lt;500/microL or an ANC that is expected to decrease to &lt;500/microL within the next 48 hours [<a href="#rid3">3</a>]. Profound neutropenia is defined as an ANC &lt;100/microL. The ANC is equal to the product of the white blood cell count (WBC) and the fraction of polymorphonuclear cells (PMNs) and band forms:</p><p>    ANC = WBC (cells/microL) x percent (PMNs + bands) ÷ 100</p><p>Neutrophilic metamyelocytes and younger forms are usually not included in this calculation (<a class="calc calc_professional" href="/d/html/13483.html" rel="external">calculator 1</a>). The risk of a clinically important infection rises as the neutrophil count falls below 500/microL  (<a class="graphic graphic_table graphicRef63903" href="/d/graphic/63903.html" rel="external">table 1</a>). (See  <a class="medical medical_review" href="/d/html/16708.html" rel="external">"Overview of neutropenic fever syndromes"</a>.)</p><p>The terms leukopenia and granulocytopenia are sometimes used interchangeably with neutropenia, although they are somewhat different. Leukopenia refers to a low total WBC, while granulocytopenia refers to a reduced number of all granulocytes (neutrophils, eosinophils, and basophils). Agranulocytosis literally means the absence of granulocytes, but the term is variably used in the literature to indicate very severe or profound neutropenia (ie, ANC &lt;100/microL, or sometimes a value that is &lt;500/microL). Clinicians focus primarily on the number of neutrophils (predominantly bands and segmented forms) since the risk of infection is most strongly related to the number of circulating neutrophils. Other granulocytes play a minimal role in the defense against bacterial and fungal infections. Thus, neutropenia is the preferred term. (See  <a class="medical medical_review" href="/d/html/8375.html" rel="external">"Overview of neutropenia in children and adolescents", section on 'Introduction'</a> and  <a class="medical medical_review" href="/d/html/90654.html" rel="external">"Approach to the adult with unexplained neutropenia", section on 'Introduction'</a>.)</p><p class="headingAnchor" id="H523774198"><span class="h2">Fever</span><span class="headingEndMark"> — </span>Fever in a neutropenic patient is usually defined as a single temperature ≥38.3°C (101°F) or a temperature ≥38°C (100.4°F) sustained over a one-hour period [<a href="#rid3">3</a>]. However, infection can occur in neutropenic patients and other immunocompromised patients in the absence of fever. This occurs more often in older adult patients and those receiving corticosteroids. Presenting signs of infection in such patients may include hypothermia, hypotension, confusion, or clinical deterioration. (See  <a class="medical medical_review" href="/d/html/16708.html" rel="external">"Overview of neutropenic fever syndromes"</a>.)</p><p class="headingAnchor" id="H523774205"><span class="h1">GRANULOCYTE COLONY STIMULATING FACTORS</span><span class="headingEndMark"> — </span>G-CSFs, which are also known as myeloid growth factors, have been evaluated for prophylactic use following the administration of chemotherapy when neutropenia is anticipated ("primary prophylaxis"), during retreatment after a previous cycle of chemotherapy that caused neutropenic fever ("secondary prophylaxis"), and to shorten the duration of severe chemotherapy-induced neutropenia in patients who have neutropenia without fever ("afebrile neutropenia"). They are generally <strong>not</strong> recommended for routine use in patients with established fever and neutropenia [<a href="#rid3">3</a>]. (See <a class="local">'Therapeutic use in patients with neutropenia'</a> below.)</p><p>The likelihood of developing neutropenic fever in patients treated with a given chemotherapy regimen is the primary factor that determines whether or not prophylactic CSFs are indicated. The incidence of neutropenic fever following treatment is influenced by the intensity of chemotherapy, the presence and degree of injury to the gastrointestinal mucosa, the presence of underlying damage to the patient's hematopoietic stem cells, the concurrent use of radiation, and the overall clinical status of the patient (ie, age and comorbid conditions).</p><p class="headingAnchor" id="H523774212"><span class="h2">Primary prophylaxis</span><span class="headingEndMark"> — </span>Primary prophylaxis refers to the initiation of G-CSFs during the first cycle of myelosuppressive chemotherapy, with the goal of preventing neutropenic complications throughout all of the chemotherapy cycles. Primary prophylaxis may be used to decrease the incidence of neutropenic fever and the need for hospitalization. Primary prophylaxis may also be used to maintain dose-dense or dose-intense chemotherapy strategies that have survival benefits, or if reductions in chemotherapy dose-intensity or dose-density are known to be associated with a poorer prognosis.</p><p class="headingAnchor" id="H523774219"><span class="h3">Indications, benefits, and guidelines</span><span class="headingEndMark"> — </span>The updated 2015 guidelines from the American Society of Clinical Oncology (ASCO), updated 2016 guidelines from the European Society for Medical Oncology (ESMO), 2010 guidelines from the Infectious Diseases Society of America (IDSA), and consensus-based guidelines from the National Comprehensive Cancer Network (NCCN) all recommend primary prophylaxis when the anticipated incidence of neutropenic fever is approximately 20 percent or higher with a given regimen [<a href="#rid3">3-7</a>]. Previous guidelines had recommended a cut-off of 40 percent [<a href="#rid8">8</a>]. The change in recommendation was driven by randomized trials showing that primary prophylaxis was cost effective when the risk of neutropenic fever with a specific regimen exceeded 20 percent [<a href="#rid9">9,10</a>].</p><p>This benchmark may change, given the high cost of treatment for neutropenic fever, which typically involves hospitalization [<a href="#rid11">11</a>]. Furthermore, at least some data suggest that rates of febrile neutropenia are much higher in observational cohorts than they are in randomized trials. In one systematic review, after adjusting for age, chemotherapy intent, and regimen, a 13 percent rate of febrile neutropenia in randomized trial populations translated into a 20 percent rate in observational studies [<a href="#rid12">12</a>]. Large population-based studies are needed to confirm febrile neutropenia rates in the real world. Until then, it is reasonable to maintain the 20 percent benchmark for use of primary prophylaxis and to individualize the use of primary prophylaxis in patients receiving regimens that have a risk between 10 and 20 percent based on other risk factors for increased complications from prolonged neutropenia.</p><p>Evidence from multiple randomized trials and meta-analyses supports the benefit of primary prophylaxis in reducing the frequency of hospitalization for antibiotic therapy, documented infection, and rates of neutropenic fever in adults [<a href="#rid13">13-17</a>]. The impact on survival (both short-term and long-term) is less clear [<a href="#rid18">18</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>In a meta-analysis that included 3493 patients treated in 17 randomized controlled trials [<a href="#rid13">13</a>], primary prophylaxis was associated with a 46 percent decrease in the risk of neutropenic fever (relative risk 0.54, 95% CI 0.43-0.67), a 45 percent decrease in infection-related mortality (relative risk 0.55, 95% CI 0.33-0.90), and a 40 percent decrease in all-cause mortality during the chemotherapy period (relative risk 0.60, 95% CI 0.43-0.87). This meta-analysis was not able to address the impact of primary prophylaxis on disease-free or cancer-specific survival.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Another meta-analysis of 148 trials of primary CSF prophylaxis in patients with cancer or undergoing hematopoietic cell transplant (HCT) also found a significant decrease in the rates of documented infections and neutropenic fever but could not confirm a reduction in short-term all-cause mortality or infection-related death [<a href="#rid14">14</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Yet another meta-analysis focusing on 61 randomized controlled trials comparing chemotherapy with or without CSF support and reporting all-cause mortality with at least two years of follow-up concluded that primary prophylaxis modestly but significantly reduced all-cause mortality (relative risk 0.93, 95% CI 0.90-0.96) [<a href="#rid19">19</a>]. The impact was most pronounced (but still modest) in randomized controlled trials of dose-dense therapy (relative risk 0.89, 95% CI 0.85-0.94).</p><p></p><p>The potential benefit of primary prophylaxis in children is less clear [<a href="#rid20">20</a>].</p><p>The risk of febrile neutropenia appears to be highest during the first two cycles of chemotherapy, regardless of tumor type or chemotherapy regimen [<a href="#rid10">10,21-23</a>], leading some to question the effectiveness of G-CSF use throughout later cycles. This issue was directly addressed in a randomized trial in which 167 women receiving chemotherapy for breast cancer with an estimated &gt;20 percent risk for febrile neutropenia were randomly assigned to G-CSF during the first two cycles only, or throughout all cycles [<a href="#rid24">24</a>]. The trial was closed prematurely when an interim analysis disclosed a significantly higher rate of febrile neutropenia in the group receiving G-CSF during the first two cycles only (36 versus 10 percent). Thus, the continued use of primary G-CSF prophylaxis during all chemotherapy cycles is indicated.</p><p class="headingAnchor" id="H2893912882"><span class="h4">Estimated risk of febrile neutropenia &lt;20 percent</span><span class="headingEndMark"> — </span>Guidelines, including those from the NCCN [<a href="#rid7">7</a>], specifically recommend <strong>against</strong> the routine administration of G-CSFs for primary prophylaxis in previously untreated adult patients receiving chemotherapy regimens with a low probability (&lt;10 percent) of causing fever during anticipated periods of neutropenia [<a href="#rid3">3-6</a>]. However, primary prophylaxis may be appropriate in a number of clinical settings in which the estimated risk of neutropenic fever is between 10 and 20 percent [<a href="#rid4">4,6,25</a>]. Factors to consider when assessing the risk of a febrile neutropenic episode in patients undergoing cytotoxic chemotherapy for malignancy are summarized in the table  (<a class="graphic graphic_table graphicRef119565" href="/d/graphic/119565.html" rel="external">table 2</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Primary prophylaxis may be indicated in patients who are being treated with curative intent (eg, lymphoma, adjuvant treatment for breast cancer, testicular cancer) to reduce the likelihood of dose-limiting neutropenia [<a href="#rid18">18,26-28</a>]. The benefit of CSFs in this setting was illustrated in a controlled trial in which 80 patients with high-grade non-Hodgkin lymphoma were randomly assigned to receive VAPEC-B chemotherapy alone or with daily G-CSF [<a href="#rid26">26</a>]. The use of G-CSF was associated with less grade 4 neutropenia (37 versus 85 percent), less neutropenic fever (22 versus 44 percent), and a lesser likelihood of chemotherapy dose reduction (10 versus 33 percent).</p><p></p><p class="bulletIndent1">Updated 2015 guidelines from ASCO specifically recommend primary prophylaxis with CSFs for selected situations [<a href="#rid4">4</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients 65 and older with diffuse aggressive lymphoma who are being treated with curative chemotherapy, particularly in the presence of comorbidities [<a href="#rid4">4</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients receiving dose-dense chemotherapy regimens that are supported by convincing efficacy data (eg, adjuvant treatment of high-risk breast cancer; high-dose-intensity <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a>, <a class="drug drug_general" data-topicid="10044" href="/d/drug information/10044.html" rel="external">vinblastine</a>, <a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">doxorubicin</a>, and <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> for urothelial cancer) [<a href="#rid4">4</a>]. (See  <a class="medical medical_review" href="/d/html/788.html" rel="external">"Selection and administration of adjuvant chemotherapy for HER2-negative breast cancer", section on 'Importance of chemotherapy schedule'</a> and  <a class="medical medical_review" href="/d/html/2991.html" rel="external">"Neoadjuvant treatment options for muscle-invasive urothelial bladder cancer"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In other situations, they recommend secondary rather than primary prophylaxis following a neutropenic complication from a prior cycle of chemotherapy.</p><p></p><p class="bulletIndent1">An important point is that controversy has surrounded the use of G-CSFs for patients with Hodgkin lymphoma undergoing chemotherapy with bleomycin-containing regimens, especially ABVD (<a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">doxorubicin</a>, <a class="drug drug_general" data-topicid="9160" href="/d/drug information/9160.html" rel="external">bleomycin</a>, <a class="drug drug_general" data-topicid="10044" href="/d/drug information/10044.html" rel="external">vinblastine</a>, and <a class="drug drug_general" data-topicid="9316" href="/d/drug information/9316.html" rel="external">dacarbazine</a>), given a possible increase in pulmonary toxicity. However, this toxicity potential is unclear for regimens such as BEACOPP (bleomycin, <a class="drug drug_general" data-topicid="8430" href="/d/drug information/8430.html" rel="external">etoposide</a>, doxorubicin, <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a>, <a class="drug drug_general" data-topicid="10045" href="/d/drug information/10045.html" rel="external">vincristine</a>, <a class="drug drug_general" data-topicid="9815" href="/d/drug information/9815.html" rel="external">procarbazine</a>, <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a>) or VEPEMB (vinblastine, cyclophosphamide, procarbazine, <a class="drug drug_general" data-topicid="9808" href="/d/drug information/9808.html" rel="external">prednisolone</a>, etoposide, <a class="drug drug_general" data-topicid="9660" href="/d/drug information/9660.html" rel="external">mitoxantrone</a>, bleomycin) for non-Hodgkin lymphoma. Clinicians should be alert to the signs and symptoms of this complication in such patients. An increase in bleomycin pulmonary toxicity has not been reported with G-CSF use in bleomycin-containing testicular cancer chemotherapy regimens [<a href="#rid28">28</a>]. (See  <a class="medical medical_review" href="/d/html/4689.html" rel="external">"Initial treatment of advanced (stage III-IV) classic Hodgkin lymphoma", section on 'BEACOPP chemotherapy'</a> and  <a class="medical medical_review" href="/d/html/4689.html" rel="external">"Initial treatment of advanced (stage III-IV) classic Hodgkin lymphoma", section on 'Older adults'</a> and  <a class="medical medical_review" href="/d/html/4316.html" rel="external">"Bleomycin-induced lung injury", section on 'Colony stimulating factors'</a> and  <a class="medical medical_review" href="/d/html/4316.html" rel="external">"Bleomycin-induced lung injury", section on 'Risk factors'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>High-risk patients who are treated with less myelosuppressive regimens may also benefit from prophylactic CSFs if they have one or more risk factors for febrile neutropenia [<a href="#rid25">25</a>]. The key factors associated with an increased risk of neutropenic events include age &gt;65 years [<a href="#rid29">29-31</a>], preexisting neutropenia or extensive bone marrow involvement by tumor [<a href="#rid31">31,32</a>], more advanced cancer [<a href="#rid33">33</a>], poor performance and/or nutritional status [<a href="#rid31">31</a>], renal or hepatic dysfunction [<a href="#rid32">32</a>], or in the case of epithelial ovarian cancer, extensive prechemotherapy surgery, particularly if it included a bowel resection [<a href="#rid34">34</a>].</p><p></p><p class="bulletIndent1">In addition, NCCN guidelines include previous chemotherapy or radiation therapy (RT), and recent surgery and/or open wounds as potential risk factors that should be considered when evaluating a patient's overall risk for febrile neutropenia [<a href="#rid7">7</a>]. ESMO guidelines also suggest that primary prophylaxis be considered in patients with reduced bone marrow reserve due to extensive RT or in patients who are neutropenic in the context of HIV infection [<a href="#rid6">6</a>]. Formal clinical risk prediction models have been validated to assist in clinical decision making [<a href="#rid32">32</a>].</p><p></p><p class="bulletIndent1">Factors to consider when assessing the risk of a febrile neutropenic episode in patients undergoing cytotoxic chemotherapy for malignancy are summarized in the table  (<a class="graphic graphic_table graphicRef119565" href="/d/graphic/119565.html" rel="external">table 2</a>) [<a href="#rid6">6,32</a>].</p><p></p><p class="headingAnchor" id="H523774226"><span class="h3">Use with concomitant chemoradiotherapy</span><span class="headingEndMark"> — </span>For treatment of some solid tumors, chemotherapy is given concurrently with RT in an effort to increase local control and survival [<a href="#rid35">35,36</a>]. Combined modality treatment also increases the incidence of neutropenic fever compared with RT alone [<a href="#rid35">35,36</a>].</p><p>However, caution must be used in this setting as the use of G-CSFs has been associated with adverse outcomes, as illustrated by the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Use of granulocyte-macrophage colony stimulating factor (GM-CSF) has been associated with a higher incidence of thrombocytopenia and other complications when given with concurrent chemoradiotherapy. This was illustrated in a Southwest Oncology Group (SWOG) trial in which 215 patients with small cell lung cancer were randomly assigned to receive concurrent chemotherapy and thoracic RT with or without GM-CSF [<a href="#rid37">37</a>]. The incidence of grade 3 and 4 thrombocytopenia was significantly higher in the GM-CSF arm (91 versus 18 percent), and there were more treatment-related deaths among those receiving GM-CSF (9 versus 1, respectively). This increase in toxicity may be specific to thoracic chemoradiotherapy and/or GM-CSF. However, because of these data, many clinicians avoid CSFs in patients receiving concurrent chemoradiotherapy for lung cancer outside of a clinical trial setting. (See  <a class="medical medical_review" href="/d/html/4633.html" rel="external">"Extensive-stage small cell lung cancer: Initial management", section on 'Investigational approaches'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a trial of concurrent chemoradiotherapy with hyperfractionated accelerated RT for locally advanced oropharyngeal and hypopharyngeal cancer, patients randomized to prophylactic G-CSF experienced significantly reduced locoregional tumor control [<a href="#rid38">38</a>]. Although it is unclear if this conclusion is applicable to all squamous cancers of the head and neck, these findings suggest that G-CSF should be used cautiously, if at all, during concomitant chemoradiotherapy for head and neck cancer. (See  <a class="medical medical_review" href="/d/html/3392.html" rel="external">"Locally advanced squamous cell carcinoma of the head and neck: Approaches combining chemotherapy and radiation therapy", section on 'Granulocyte colony-stimulating factor'</a>.)</p><p></p><p class="headingAnchor" id="H523774233"><span class="h2">Secondary prophylaxis</span><span class="headingEndMark"> — </span>Secondary prophylaxis refers to the administration of a G-CSF in subsequent chemotherapy cycles after neutropenic fever has occurred in a prior cycle. A prior episode of fever during neutropenia is a risk factor for developing fever during neutropenia in later cycles, with recurrences noted in 50 to 60 percent of patients [<a href="#rid21">21,39,40</a>]. Secondary prophylaxis with CSFs reduces this risk by approximately one-half [<a href="#rid41">41</a>].</p><p>The concept of secondary prophylaxis also includes the use of a G-CSF to speed recovery from neutropenia due to a previous cycle of chemotherapy, thus preventing delay in the administration of a subsequent chemotherapy cycle. There are no data proving the benefit of CSFs in this setting, and it is not clear that they are needed. At least some data support the safety of administering adjuvant anthracycline-containing chemotherapy without CSF support and without the need for dose reduction in women with uncomplicated neutropenia whose neutrophil count on the day of planned treatment is ≤1500 per microL [<a href="#rid42">42</a>].</p><p>In both of these settings, the goal of secondary prophylaxis is to maintain chemotherapy dose intensity while avoiding dose reduction. However, dose reduction after an episode of severe neutropenia should be considered the primary therapeutic option, unless chemotherapy is being administered for the treatment of curable tumors (eg, lymphoma, germ cell cancer, early stage breast cancer) [<a href="#rid4">4</a>]. In theory, the survival benefit associated with potentially curative chemotherapy is preserved as long as doses are not reduced below a critical level. However, no published regimen has ever shown improved disease-free or overall survival when secondary prophylaxis was instituted and the dose of chemotherapy maintained in any setting, including these potentially curable tumors.</p><p>ASCO and ESMO guidelines suggest that secondary prophylaxis with granulocyte CSFs be limited to patients who experience a neutropenic complication (ie, fever, treatment delay) from a prior cycle of chemotherapy (for which primary prophylaxis was not received) if reduced dose intensity might compromise treatment outcome [<a href="#rid4">4,6</a>]. We agree with these recommendations.</p><p class="headingAnchor" id="H1183953"><span class="h2">Therapeutic use in patients with neutropenia</span></p><p class="headingAnchor" id="H523774240"><span class="h3">Neutropenia without fever</span><span class="headingEndMark"> — </span>There is no established role for the use of CSFs in afebrile patients who have already developed severe neutropenia after chemotherapy, and we recommend against their use. The lack of benefit from CSFs in this setting was illustrated in a controlled trial in which 138 afebrile outpatients with severe chemotherapy-induced neutropenia (absolute neutrophil count [ANC] ≤500/microL) were randomly assigned to G-CSF or placebo until the ANC recovered to at least 500/microL [<a href="#rid43">43</a>]. The duration of severe neutropenia was modestly shorter with G-CSF (two versus four days), but there was no effect on the rate of hospitalization or number of culture-positive infections.</p><p class="headingAnchor" id="H1163951"><span class="h3">Neutropenic fever</span><span class="headingEndMark"> — </span>The use of therapeutic granulocyte CSFs in patients with established fever and neutropenia is controversial; the results of randomized trials have been mixed. A 2014 meta-analysis of 14 randomized trials (a total of 1553 participants) addressing the role of CSFs plus antibiotics in febrile neutropenia came to the following conclusions [<a href="#rid44">44</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>The methodologic quality was low to moderate across different outcomes.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Use of CSFs did not significantly improve overall mortality (hazard ratio [HR] 0.74, 95% CI 0.47-1.16) or infection-related mortality (HR 0.75, 95% CI 0.47-1.20) as compared with antibiotics alone.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Individuals who received CSFs were significantly less likely to be hospitalized for longer than 10 days (risk ratio 0.65, 95% CI 0.44-0.95), and they had significantly shorter duration of neutropenia (standardized mean difference [SMD] -1.7 days, 95% CI -2.65 to -0.76), shorter duration of antibiotic use (SMD -1.50 days, 95% CI -2.83 to -0.18), and faster recovery from fever (SMD -0.49 days, 95% CI -0.90 to -0.09).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Use of CSFs was associated with a significantly higher incidence of bone or joint pain or flu-like symptoms (risk ratio 1.59, 95% CI 1.04-2.42).</p><p></p><p>Clinical prediction models have been developed to help prospectively identify patients with cancer who are at high risk of complications as a result of neutropenic fever (see  <a class="medical medical_review" href="/d/html/16888.html" rel="external">"Risk assessment of adults with chemotherapy-induced neutropenia"</a>). However, while a number of clinical characteristics may provide prognostic information regarding the outcomes of patients with neutropenic fever, predictive models are needed to better identify high-risk patients who may benefit from the addition of granulocyte CSFs to antibiotics. A risk model for mortality in hospitalized cancer patients with neutropenic fever has been reported in which several independent risk factors were identified, including age ≥65, cancer type (leukemia, lung cancer), comorbidities (heart failure, pulmonary embolus, lung, renal, liver, cerebrovascular disease), and infectious complications (hypotension, pneumonia, bacteremia, fungal infection) [<a href="#rid45">45</a>].</p><p>Recommendations from expert groups for use of therapeutic CSFs in established fever and neutropenia differ:</p><p class="bulletIndent1"><span class="glyph">●</span>Given their cost and potential adverse effects, as well as the lack of consistent clinical data demonstrating benefit, guidelines from the IDSA recommend against the use of G-CSFs for patients with established fever and neutropenia [<a href="#rid3">3</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Guidelines from ASCO also recommend against routine use of CSFs in this setting, but they suggest that CSFs be "considered" for patients at high risk for infection-associated complications or who have prognostic factors that are predictive of a poor clinical outcome [<a href="#rid4">4</a>]. These features include expected prolonged (&gt;10 days) or profound (&lt;100 cells/microL) neutropenia, age &gt;65, pneumonia or other clinically documented infections, sepsis syndrome, invasive fungal infection, prior episode of febrile neutropenia, or being hospitalized at the time of the development of fever.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>ESMO guidelines do not address this issue specifically [<a href="#rid6">6</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The NCCN recommends that granulocyte CSF be continued in patients who are receiving prophylactic CSFs at the time of the presentation with neutropenic fever [<a href="#rid7">7</a>]. They also suggest "consideration" of CSFs in patients who did not receive prophylactic CSFs and in whom there are risk factors for an infection-related complication, similar to those outlined in the ASCO guideline.</p><p></p><p>We follow the guidelines from ASCO. Given that it takes several days for CSF to produce a response with increased circulating neutrophils, antibiotics will always work faster. CSFs can also be a useful adjunct for patients who remain neutropenic and febrile and are not rapidly responding to antibiotics.</p><p class="headingAnchor" id="H938520"><span class="h2">GM-CSF versus G-CSF and biosimilars</span><span class="headingEndMark"> — </span>Many placebo-controlled trials have shown that both G-CSF and GM-CSF (<a class="drug drug_general" data-topicid="9878" href="/d/drug information/9878.html" rel="external">sargramostim</a>) are effective at reducing the incidence of neutropenic fever and infectious complications in cancer patients receiving chemotherapy. In different markets, G-CSF is commercially available as <a class="drug drug_general" data-topicid="8446" href="/d/drug information/8446.html" rel="external">filgrastim</a> (Neupogen) and lenograstim (Granocyte, Neutrogin, Myelostim). Several biosimilar forms of filgrastim are available worldwide. Updated guidelines from ASCO suggest that all of these preparations of G-CSF, including biosimilars, can be used for the prevention of treatment-related febrile neutropenia and that the choice of agent should be based on convenience, cost, and clinical situation [<a href="#rid4">4</a>].</p><p>There are only limited comparative data of G-CSF versus GM-CSF, which are conflicting about both safety and efficacy [<a href="#rid46">46-51</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Only one randomized trial directly compared G-CSF with GM-CSF in 181 afebrile cancer patients undergoing myelosuppressive chemotherapy [<a href="#rid46">46</a>]. Patients receiving G-CSF had a one-day shorter time to recovery from neutropenia, but the difference was neither clinically meaningful nor statistically significant.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A prospective medication use evaluation study found similar efficacy, safety, and tolerability with G-CSF and GM-CSF [<a href="#rid47">47</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Two retrospective studies reported more adverse events and/or neutropenic fever with GM-CSF than with G-CSF [<a href="#rid48">48,49</a>]. By contrast, a retrospective matched pair cohort analysis derived from a health insurance claims database (and partially funded by the manufacturer of GM-CSF) concluded that patients receiving GM-CSF after outpatient chemotherapy had a lower risk of infection-related hospitalization compared with those receiving G-CSF or <a class="drug drug_general" data-topicid="10154" href="/d/drug information/10154.html" rel="external">pegfilgrastim</a>, a pegylated formulation of G-CSF that has a prolonged half-life [<a href="#rid50">50</a>].</p><p></p><p>In the absence of additional comparative data from randomized controlled trials, there is no basis for recommending one CSF over the other for prophylaxis of infection during chemotherapy-induced neutropenia. However, in practice, most institutions use G-CSF.</p><p class="headingAnchor" id="H523774247"><span class="h2">Dose and timing of G-CSF and GM-CSF</span><span class="headingEndMark"> — </span>When used for primary and secondary prophylaxis, the recommended dose of G-CSF (<a class="drug drug_general" data-topicid="8446" href="/d/drug information/8446.html" rel="external">filgrastim</a>, filgrastim-sndz, tbo-filgrastim) is 5 mcg/kg per day and for GM-CSF (<a class="drug drug_general" data-topicid="9878" href="/d/drug information/9878.html" rel="external">sargramostim</a>), 250 mcg/m<sup>2</sup> per day. To reduce cost, the dose is usually rounded off to the nearest vial size. Therapy is usually begun 24 to 72 hours after cessation of chemotherapy.</p><p>There is no consensus as to the optimal duration for either primary or secondary prophylaxis, and several strategies have been suggested:</p><p class="bulletIndent1"><span class="glyph">●</span>Year 2000 guidelines from ASCO suggest daily growth factor administration with twice weekly monitoring of blood counts until the ANC reaches 5000 to 10,000/microL; continuation until clinically adequate neutrophil recovery is achieved is a reasonable alternative [<a href="#rid8">8</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>NCCN guidelines suggest daily administration until the post-nadir ANC recovers to normal or near-normal levels by laboratory standards [<a href="#rid52">52</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Several dose-dense chemotherapy regimens utilize a fixed schedule of G-CSF administration (eg, dose-dense AC plus T chemotherapy for adjuvant therapy of breast cancer suggests seven consecutive days of G-CSF  (<a class="graphic graphic_table graphicRef55933" href="/d/graphic/55933.html" rel="external">table 3</a>)). However, at least one randomized trial suggests that daily administration of G-CSF for 5 days in the setting of primary prophylaxis is at least as effective as 7 or 10 days of daily administration, less costly, and associated with fewer adverse events driving G-CSF schedule changes [<a href="#rid53">53</a>].</p><p></p><p>In our view, either approach is reasonable. However, in either case, premature discontinuation of G-CSF or GM-CSF, before the nadir of the white blood cell count has been reached, should be avoided. These data may not apply much to women receiving breast cancer treatment in the United States where use of <a class="drug drug_general" data-topicid="10154" href="/d/drug information/10154.html" rel="external">pegfilgrastim</a> is more prominent. Furthermore, factoring in the cost of weekly complete blood count to monitor the neutrophil count and having the patient return to clinic daily for an injection, there might be minimal cost savings with either strategy.</p><p>Shorter administration schedules may have similar efficacy with lower cost and increased convenience for the patient [<a href="#rid54">54</a>]. However, these approaches have not been compared with standard regimens in randomized trials.</p><p>Because of the potential sensitivity of rapidly dividing myeloid cells to cytotoxic chemotherapy, growth factors should be discontinued several days before the next chemotherapy treatment and they should not be given on the same day as chemotherapy [<a href="#rid55">55</a>]. Experience from clinical trials indicates that myelosuppression is more profound if the myeloid growth factors were given immediately prior to or on the same day as the chemotherapy. For the same reason, growth factors should not be given concurrently with RT directed at portals containing active marrow.</p><p class="headingAnchor" id="H523774254"><span class="h2">Long-acting agents</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10154" href="/d/drug information/10154.html" rel="external">Pegfilgrastim</a>, a pegylated formulation of G-CSF, was the first long-acting formulation of G-CSF. Since then, several other similar agents have shown efficacy. Choice between them is based on availability and cost, given comparable efficacy and side effects.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pegfilgrastim</strong> – <a class="drug drug_general" data-topicid="10154" href="/d/drug information/10154.html" rel="external">Pegfilgrastim</a> has a prolonged half-life, permitting the administration of a single dose rather than daily administration. The recommended dose (6 mg in adults, 100 mcg/kg [maximum 6 mg] in children [<a href="#rid56">56</a>]) is given 24 hours after chemotherapy [<a href="#rid57">57</a>], with at least 14 days elapsing until the next planned chemotherapy dose. Blood counts are typically not routinely monitored in patients receiving pegfilgrastim.</p><p></p><p class="bulletIndent1">Multiple randomized trials and a meta-analysis have shown that <a class="drug drug_general" data-topicid="10154" href="/d/drug information/10154.html" rel="external">pegfilgrastim</a> is at least as effective as and more convenient to administer than G-CSF for primary prophylaxis in patients requiring CSF treatment during myelosuppressive chemotherapy [<a href="#rid58">58-63</a>]. Many trials in fact suggest better efficacy for pegfilgrastim over G-CSF [<a href="#rid63">63</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Related agents</strong> – Lipegfilgrastim, a glycoPEGylated, long-acting form of recombinant human <a class="drug drug_general" data-topicid="8446" href="/d/drug information/8446.html" rel="external">filgrastim</a>, which is marketed as Lonquex, is approved in the United Kingdom and by the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.ema.europa.eu%2Fen%2Fmedicines%2Fhuman%2FEPAR%2Flonquex&amp;token=NyRkA1K%2BEfcjom0B%2BqrukqUS8%2FbzxUMboZEpDyyUteToBiaVhMVuTIK4R8Ue%2FVxohb9uj4HjCpalWlL5g78p3Q%3D%3D&amp;TOPIC_ID=16889" target="_blank">European Medicines Agency (EMA)</a>, but it is not approved in the United States or Canada. Pegteograstim, marketed as Neurapeg, is another formulation of pegylated G-CSF that is approved in South Korea. Efficacy and safety of both agents appear similar to <a class="drug drug_general" data-topicid="10154" href="/d/drug information/10154.html" rel="external">pegfilgrastim</a> [<a href="#rid63">63-66</a>].</p><p></p><p class="bulletIndent2">Four biosimilar forms of <a class="drug drug_general" data-topicid="10154" href="/d/drug information/10154.html" rel="external">pegfilgrastim</a> (pegfilgrastim-jmdb [Fulphila], pegfilgrastim-cbqv [Udenyca], pegfilgrastim-bmez [Ziextenzo], and pegfilgrastim-apgf [Nyvepria]) were approved in the United States between 2018 and 2020.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efbemalenograstim alfa</strong> – <a class="drug drug_general" data-topicid="143497" href="/d/drug information/143497.html" rel="external">Efbemalenograstim alfa</a>, a leukocyte growth factor, is a recombinant fusion protein consisting of human G-CSF, a 16 amino-acid linker, and the Fc portion of human IgG2 [<a href="#rid67">67</a>]. It binds to specific cell surface receptors to stimulate proliferation and activation of leukocytes.</p><p></p><p class="bulletIndent1">In a randomized trial (GC-627-04 [NCT02872103]) in 122 patients with breast cancer receiving <a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">doxorubicin</a> 60 mg/m<sup>2</sup> and <a class="drug drug_general" data-topicid="9381" href="/d/drug information/9381.html" rel="external">docetaxel</a> 75 mg/m<sup>2</sup> every 21 days for up to four cycles, those randomly assigned to <a class="drug drug_general" data-topicid="143497" href="/d/drug information/143497.html" rel="external">efbemalenograstim alfa</a> on cycle 1, day 2 of chemotherapy experienced a shorter duration of severe (grade 4) neutropenia during this cycle than those assigned to placebo (1.4 versus 4.3 days) [<a href="#rid67">67</a>]. Febrile neutropenia was also lower (4.8 versus 26 percent).</p><p></p><p class="bulletIndent1">In a separate randomized trial (GC-627-05 [NCT03252431]) in 393 patients with breast cancer receiving <a class="drug drug_general" data-topicid="9381" href="/d/drug information/9381.html" rel="external">docetaxel</a> 75 mg/m<sup>2</sup> and <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> 600 mg/m<sup>2</sup> every 21 days for up to four cycles, <a class="drug drug_general" data-topicid="143497" href="/d/drug information/143497.html" rel="external">efbemalenograstim alfa</a> and <a class="drug drug_general" data-topicid="10154" href="/d/drug information/10154.html" rel="external">pegfilgrastim</a> resulted in the same mean number of days of severe neutropenia in cycle 1 (0.2 days with either agent) [<a href="#rid67">67</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Eflapegrastim</strong> – <a class="drug drug_general" data-topicid="139627" href="/d/drug information/139627.html" rel="external">Eflapegrastim</a> is a long-acting form of G-CSF, which consists of a recombinant human G-CSF analog conjugated to a human aglycosylated IgG4 Fc fragment with a short polyethylene glycol linker. The addition of an Fc fragment and the large size of the molecule extends drug half-life by decreasing clearance, and there is increased uptake in the bone marrow, presumably due to the interaction of the Fc fragment with receptors on surface of endothelial cells [<a href="#rid68">68,69</a>]. The end result is a shortened duration of chemotherapy-associated neutropenia.</p><p></p><p class="bulletIndent1">In two separate randomized phase III trials, patients with early stage breast cancer treated with four cycles of standard dose <a class="drug drug_general" data-topicid="9381" href="/d/drug information/9381.html" rel="external">docetaxel</a> plus <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> were randomly assigned to fixed-dose <a class="drug drug_general" data-topicid="139627" href="/d/drug information/139627.html" rel="external">eflapegrastim</a> (13.2 mg containing 3.6 mg G-CSF) or <a class="drug drug_general" data-topicid="10154" href="/d/drug information/10154.html" rel="external">pegfilgrastim</a> (containing 6 mg G-CSF), both administered on day 2, 24 hours after the end of chemotherapy [<a href="#rid70">70,71</a>]. Efficacy and safety were comparable, and despite the lower G-CSF dose, the incidence of adverse events (ie, musculoskeletal pain, injection site reactions) was not lower with eflapegrastim in either trial. In a preliminary report of a pooled analysis of both studies (totaling 643 patients), eflapegrastim modestly but significantly reduced the mean duration of severe neutropenia, which was defined as ANC &lt;500/microL (0.24 versus 0.36 days, p = 0.029) and the overall risk of severe neutropenia during cycle 1 (17.5 versus 24 percent, relative risk reduction 27 percent, p = 0.043) compared with pegfilgrastim [<a href="#rid72">72</a>]. Benefits were more pronounced in those with weight &gt;75 kg (54 percent of the study population).</p><p></p><p class="bulletIndent1">Largely based on these results, in September 2022, the US Food and Drug Administration approved <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2022%2F761148Orig1s000Corrected_lbl.pdf&amp;token=D%2Fjya%2B6zhzYy8zf8Q%2BHLGQY5e2KOfAZan43k%2Fgb16AIloGhS5IIQLO%2FV4KTFYHpE10ROwQNGedOeFFSpm3TzuJRfDY0n7P0Jpta%2FwGTBBBt2H0pPH2KlRhkgR5QH6uL%2F&amp;TOPIC_ID=16889" target="_blank">eflapegrastim injection</a> to decrease the incidence of infection in adult patients with nonmyeloid malignancies receiving myelosuppressive anticancer drugs associated with a clinically significant incidence of febrile neutropenia [<a href="#rid73">73</a>].</p><p></p><p class="bulletIndent1">Given the available data, the medications above appear clinically similar when used as supportive care for patients receiving <a class="drug drug_general" data-topicid="9381" href="/d/drug information/9381.html" rel="external">docetaxel</a> and <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a>. Their use will be determined largely by their relative acquisition costs.</p><p></p><p class="headingAnchor" id="H523774268"><span class="h2">Possible stimulation of malignancy</span><span class="headingEndMark"> — </span>Because myeloid growth factor receptors are expressed by several hematopoietic and nonhematopoietic cell types, there has been a concern that certain malignant cell lineages might respond to therapy with a granulocyte CSF, potentially worsening the underlying condition or triggering the development of malignancy in a susceptible individual. As an example of such a concern, the use of G-CSFs in patients undergoing induction therapy for acute myeloid leukemia (AML) has been limited by evidence that malignant myeloblasts express receptors for such growth factors. Prophylactic antibacterial and antifungal agents are more commonly used during chemotherapy for AML rather than CSFs. The potential role of CSFs during induction therapy for AML is discussed in greater detail elsewhere. (See  <a class="medical medical_review" href="/d/html/4530.html" rel="external">"Acute myeloid leukemia: Management of medically unfit adults"</a> and  <a class="medical medical_review" href="/d/html/4525.html" rel="external">"Acute myeloid leukemia: Induction therapy in medically fit adults", section on 'Adjunctive care'</a>.)</p><p>Several observational studies report that the use of CSFs during chemotherapy for other malignancies such as breast and lung cancer is associated with a small but likely real increased risk of therapy-related hematologic neoplasms, including AML, myelodysplastic syndrome (MDS), and possibly acute lymphoblastic leukemia/lymphocytic lymphoma (ALL/LL) [<a href="#rid74">74-77</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>This issue was addressed in a systematic review of 64 randomized trials of chemotherapy with or without G-CSF for a variety of neoplasms [<a href="#rid74">74</a>]. Although a secondary malignancy (AML/MDS) was reported in significantly more patients treated with G-CSF (relative risk 1.85, 95% CI 1.19-2.88), all-cause mortality was significantly lower in patients receiving chemotherapy with G-CSF (relative risk for death 0.92, 95% CI 0.90-0.95), and greater reductions in mortality were observed in patients who received dose-dense chemotherapy regimens with G-CSF support compared with controls receiving no G-CSF support (relative risk for death 0.86, 95% CI 0.80-0.92).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Additional data are available from a French population-based analysis of women who had been diagnosed with an incident breast cancer between 2007 and 2015, and received chemotherapy within six months following primary surgery; among the total 122,373 breast cancer survivors, 39 percent received chemotherapy alone and 61 percent chemotherapy plus G-CSF [<a href="#rid75">75</a>]. The specific chemotherapy regimens were not described. At a median follow-up of 4.9 years (range 2.8-7.2), use of G-CSF was associated with a nonsignificant increase in the risk of AML (adjusted hazard ratio [aHR] 1.3, 95% CI 1.0-1.7), MDS (aHR 1.3, 95% CI 0.9-1.8), and of ALL/LL (aHR 2.0, 95% CI 1.0-4.4). A dose-effect relationship was evident for ALL/LL (1 to 3 cycles, aHR 1.5, 95% CI 0.5-3.9; for 4+ cycles, aHR 2.3, 95% CI 1.0-5.1) analysis, although there was a trend for an increasing hazard rate for both AML and MDS with increased cycles of G-CSF.</p><p></p><p>Thus, while the use of myeloid growth factors during chemotherapy increases the risk of a therapy-related hematologic neoplasm, the absolute magnitude of the risk is small, and the risk is probably outweighed by the benefits of using CSFs in this setting. Nevertheless, in January 2021, the United States Prescribing Information for both <a class="drug drug_general" data-topicid="8446" href="/d/drug information/8446.html" rel="external">filgrastim</a> and <a class="drug drug_general" data-topicid="10154" href="/d/drug information/10154.html" rel="external">pegfilgrastim</a> was modified to indicate a risk of both MDS and AML with both agents after chemotherapy and/or radiotherapy for lung cancer, and that patients should be monitored for signs and symptoms of AML/MDS in these settings [<a href="#rid78">78,79</a>].</p><p>The addition of G-CSF to high intensity, rapidly repeating courses of chemotherapy containing both alkylating agents and topoisomerase II inhibitors, such as <a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">doxorubicin</a> plus <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> followed by <a class="drug drug_general" data-topicid="9735" href="/d/drug information/9735.html" rel="external">paclitaxel</a> for the adjuvant treatment of breast cancer, has been associated with therapy-related myeloid leukemia with a particularly short latency period of two to three years. These data and this subject are addressed in more detail elsewhere. (See  <a class="medical medical_review" href="/d/html/8383.html" rel="external">"Introduction to recombinant hematopoietic growth factors", section on 'Possible stimulation of malignancy'</a> and  <a class="medical medical_review" href="/d/html/745.html" rel="external">"Overview of side effects of chemotherapy for early-stage breast cancer"</a>.)</p><p class="headingAnchor" id="H523774275"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Primary prophylaxis</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Patients receiving chemotherapy</strong></p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Consistent with guidelines from the American Society of Clinical Oncology (ASCO), the Infectious Diseases Society of America, and the European Society for Medical Oncology when the expected incidence of neutropenic fever with a specific antineoplastic regimen is over 20 percent, we suggest prophylactic colony stimulating factors (CSFs) during all cycles of chemotherapy to reduce the need for hospitalization for antibiotic therapy (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). (See <a class="local">'Indications, benefits, and guidelines'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>When the estimated risk of neutropenic fever is between 10 and 20 percent, the decision to use prophylactic hematopoietic growth factor support should be individualized. Factors to consider when assessing the risk of a febrile neutropenic episode in patients undergoing cytotoxic chemotherapy for malignancy are summarized in the table  (<a class="graphic graphic_table graphicRef119565" href="/d/graphic/119565.html" rel="external">table 2</a>).</p><p></p><p class="bulletIndent3">Examples of specific patients who may be at risk for increased complications from prolonged neutropenia and for whom primary prophylaxis might be justified include individuals over age 65 and older who are receiving potentially curative therapy for diffuse aggressive lymphoma, and individuals undergoing curative-intent dose-dense chemotherapy regimens that are supported by convincing efficacy data (eg, adjuvant treatment of high-risk breast cancer; high-dose-intensity <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a>, <a class="drug drug_general" data-topicid="10044" href="/d/drug information/10044.html" rel="external">vinblastine</a>, <a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">doxorubicin</a>, and <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> for urothelial cancer).</p><p></p><p class="bulletIndent3">In other situations where patients are being treated with curative-intent therapy, secondary prophylaxis is preferred for those who develop a neutropenic complication during a prior cycle of chemotherapy. (See <a class="local">'Indications, benefits, and guidelines'</a> above.)</p><p></p><p class="bulletIndent3">However, during the COVID-19 pandemic, updated guidelines from the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.nccn.org%2Fcovid-19&amp;token=wEsKVFvqlKzpT%2BqOtddW%2FxnNKpssNy%2BEkdj3HSAg6iqxfYwOrIxT%2Fs4nYoDZGp0h&amp;TOPIC_ID=16889" target="_blank">National Comprehensive Cancer Network (NCCN)</a> and <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.asco.org%2Fasco-coronavirus-information&amp;token=j%2BtF41plvYHq0KcVLVNCgtgK5bP5P1svLL7u35O16AyeJe%2FnJ%2FpqMukdUxPrt%2BKgCNewPzz%2FQtCIV7FvaheQiQ%3D%3D&amp;TOPIC_ID=16889" target="_blank">ASCO</a> have lowered the threshold for the use of myeloid growth factors from those chemotherapy regimens which have a 20 percent or higher risk of febrile neutropenia to now include those regimens with a risk of 10 to 20 percent, which includes all of the intermediate-risk chemotherapy regimens.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Chemoradiotherapy</strong> – Given the concerns for adverse events, avoid G-CSFs in patients receiving concomitant chemoradiotherapy for either head and neck or lung cancer. (See <a class="local">'Use with concomitant chemoradiotherapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Choice of agent</strong> – In the absence of additional comparative data from randomized controlled trials, there is no basis for recommending one hematopoietic growth factor (G-CSF, granulocyte-macrophage [GM]-CSF, <a class="drug drug_general" data-topicid="10154" href="/d/drug information/10154.html" rel="external">pegfilgrastim</a>, or a biosimilar product) over the other for prophylaxis of infection during chemotherapy-induced neutropenia. (See <a class="local">'GM-CSF versus G-CSF and biosimilars'</a> above and <a class="local">'Long-acting agents'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Secondary prophylaxis</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients who had an episode of neutropenic fever after an earlier cycle of palliative chemotherapy, we suggest dose reduction or delay as the primary therapeutic option rather than routine administration of CSFs (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>However, consistent with ASCO guidelines, in circumstances in which a reduced dose or treatment delay may compromise disease-free survival, overall survival, or treatment outcomes, we suggest the use of G-CSFs for secondary prophylaxis rather than dose reduction (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Secondary prophylaxis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Therapeutic use in patients with neutropenia</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>There is no established role for G-CSFs in afebrile patients who have already developed severe neutropenia after chemotherapy, and we recommend against their use in this setting (<a class="grade" href="https://medilib.ir/uptodate/show/grade_2" rel="external">Grade 1B</a>). (See <a class="local">'Neutropenia without fever'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>We also suggest not using G-CSFs routinely as an adjunct to antibiotics for most patients with established fever and neutropenia (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). However, CSFs can be a useful adjunct for patients who remain neutropenic and febrile after the initiation of antibiotics.</p><p></p><p class="bulletIndent2">Consistent with guidelines from ASCO, we restrict use of CSFs to patients at high risk for infection-associated complications or who have prognostic factors that are predictive of a poor clinical outcome. These include expected prolonged (&gt;10 days) or profound (&lt;100 cells/microL) neutropenia, age &gt;65, pneumonia or other clinically documented infection, sepsis syndrome, invasive fungal infection, prior episode of febrile neutropenia, or being hospitalized at the time of the development of fever. (See <a class="local">'Neutropenic fever'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Caggiano V, Weiss RV, Rickert TS, Linde-Zwirble WT. Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy. Cancer 2005; 103:1916.</a></li><li><a class="nounderline abstract_t">Lyman GH, Michels SL, Reynolds MW, et al. Risk of mortality in patients with cancer who experience febrile neutropenia. Cancer 2010; 116:5555.</a></li><li><a class="nounderline abstract_t">Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis 2011; 52:e56.</a></li><li><a class="nounderline abstract_t">Smith TJ, Bohlke K, Lyman GH, et al. Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol 2015; 33:3199.</a></li><li class="breakAll">National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Ovarian Cancer Including Fallopian Tube Cancer and Primary Peritoneal Cancer. Version 2.2023. Available at: https://www.nccn.org/professionals/physician_gls/ https://www.nccn.org/professionals/physician_gls/ (Accessed on November 29, 2023).</li><li><a class="nounderline abstract_t">Klastersky J, de Naurois J, Rolston K, et al. Management of febrile neutropaenia: ESMO Clinical Practice Guidelines. Ann Oncol 2016; 27:v111.</a></li><li class="breakAll">National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology. Available at: https://www.nccn.org/professionals/physician_gls/pdf/gist.pdf (Accessed on July 25, 2023).</li><li><a class="nounderline abstract_t">Ozer H, Armitage JO, Bennett CL, et al. 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel. J Clin Oncol 2000; 18:3558.</a></li><li><a class="nounderline abstract_t">Timmer-Bonte JN, Adang EM, Smit HJ, et al. Cost-effectiveness of adding granulocyte colony-stimulating factor to primary prophylaxis with antibiotics in small-cell lung cancer. J Clin Oncol 2006; 24:2991.</a></li><li><a class="nounderline abstract_t">Vogel CL, Wojtukiewicz MZ, Carroll RR, et al. First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol 2005; 23:1178.</a></li><li><a class="nounderline abstract_t">Lathia N, Mittmann N, DeAngelis C, et al. Evaluation of direct medical costs of hospitalization for febrile neutropenia. Cancer 2010; 116:742.</a></li><li><a class="nounderline abstract_t">Truong J, Lee EK, Trudeau ME, Chan KK. Interpreting febrile neutropenia rates from randomized, controlled trials for consideration of primary prophylaxis in the real world: a systematic review and meta-analysis. Ann Oncol 2016; 27:608.</a></li><li><a class="nounderline abstract_t">Kuderer NM, Dale DC, Crawford J, Lyman GH. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol 2007; 25:3158.</a></li><li><a class="nounderline abstract_t">Sung L, Nathan PC, Alibhai SM, et al. Meta-analysis: effect of prophylactic hematopoietic colony-stimulating factors on mortality and outcomes of infection. Ann Intern Med 2007; 147:400.</a></li><li><a class="nounderline abstract_t">Cooper KL, Madan J, Whyte S, et al. Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis. BMC Cancer 2011; 11:404.</a></li><li><a class="nounderline abstract_t">Bohlius J, Herbst C, Reiser M, et al. Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphoma. Cochrane Database Syst Rev 2008; :CD003189.</a></li><li><a class="nounderline abstract_t">Wang L, Baser O, Kutikova L, et al. The impact of primary prophylaxis with granulocyte colony-stimulating factors on febrile neutropenia during chemotherapy: a systematic review and meta-analysis of randomized controlled trials. Support Care Cancer 2015; 23:3131.</a></li><li><a class="nounderline abstract_t">Bennett CL, Djulbegovic B, Norris LB, Armitage JO. Colony-stimulating factors for febrile neutropenia during cancer therapy. N Engl J Med 2013; 368:1131.</a></li><li><a class="nounderline abstract_t">Lyman GH, Dale DC, Culakova E, et al. The impact of the granulocyte colony-stimulating factor on chemotherapy dose intensity and cancer survival: a systematic review and meta-analysis of randomized controlled trials. Ann Oncol 2013; 24:2475.</a></li><li><a class="nounderline abstract_t">Pui CH, Boyett JM, Hughes WT, et al. Human granulocyte colony-stimulating factor after induction chemotherapy in children with acute lymphoblastic leukemia. N Engl J Med 1997; 336:1781.</a></li><li><a class="nounderline abstract_t">Timmer-Bonte JN, de Boo TM, Smit HJ, et al. Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: a Dutch Randomized Phase III Study. J Clin Oncol 2005; 23:7974.</a></li><li><a class="nounderline abstract_t">Martín M, Lluch A, Seguí MA, et al. Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen. Ann Oncol 2006; 17:1205.</a></li><li><a class="nounderline abstract_t">von Minckwitz G, Kümmel S, du Bois A, et al. Pegfilgrastim +/- ciprofloxacin for primary prophylaxis with TAC (docetaxel/doxorubicin/cyclophosphamide) chemotherapy for breast cancer. Results from the GEPARTRIO study. Ann Oncol 2008; 19:292.</a></li><li><a class="nounderline abstract_t">Aarts MJ, Peters FP, Mandigers CM, et al. Primary granulocyte colony-stimulating factor prophylaxis during the first two cycles only or throughout all chemotherapy cycles in patients with breast cancer at risk for febrile neutropenia. J Clin Oncol 2013; 31:4290.</a></li><li><a class="nounderline abstract_t">Weycker D, Li X, Barron R, et al. Importance of Risk Factors for Febrile Neutropenia Among Patients Receiving Chemotherapy Regimens Not Classified as High-Risk in Guidelines for Myeloid Growth Factor Use. J Natl Compr Canc Netw 2015; 13:979.</a></li><li><a class="nounderline abstract_t">Pettengell R, Gurney H, Radford JA, et al. Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: a randomized controlled trial. Blood 1992; 80:1430.</a></li><li><a class="nounderline abstract_t">Rivera E, Erder MH, Moore TD, et al. Targeted filgrastim support in patients with early-stage breast carcinoma: toward the implementation of a risk model. Cancer 2003; 98:222.</a></li><li><a class="nounderline abstract_t">Fosså SD, Kaye SB, Mead GM, et al. Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy. European Organization for Research and Treatment of Cancer, Genito-Urinary Group, and the Medical Research Council Testicular Cancer Working Party, Cambridge, United Kingdom. J Clin Oncol 1998; 16:716.</a></li><li><a class="nounderline abstract_t">Aapro M, Schwenkglenks M, Lyman GH, et al. Pegfilgrastim primary prophylaxis vs. current practice neutropenia management in elderly breast cancer patients receiving chemotherapy. Crit Rev Oncol Hematol 2010; 74:203.</a></li><li><a class="nounderline abstract_t">Tjan-Heijnen VC, Postmus PE, Ardizzoni A, et al. Reduction of chemotherapy-induced febrile leucopenia by prophylactic use of ciprofloxacin and roxithromycin in small-cell lung cancer patients: an EORTC double-blind placebo-controlled phase III study. Ann Oncol 2001; 12:1359.</a></li><li><a class="nounderline abstract_t">Dranitsaris G, Rayson D, Vincent M, et al. Identifying patients at high risk for neutropenic complications during chemotherapy for metastatic breast cancer with doxorubicin or pegylated liposomal doxorubicin: the development of a prediction model. Am J Clin Oncol 2008; 31:369.</a></li><li><a class="nounderline abstract_t">Lyman GH, Kuderer NM, Crawford J, et al. Predicting individual risk of neutropenic complications in patients receiving cancer chemotherapy. Cancer 2011; 117:1917.</a></li><li><a class="nounderline abstract_t">Moreau M, Klastersky J, Schwarzbold A, et al. A general chemotherapy myelotoxicity score to predict febrile neutropenia in hematological malignancies. Ann Oncol 2009; 20:513.</a></li><li><a class="nounderline abstract_t">Sharma S, Rezai K, Driscoll D, et al. Characterization of neutropenic fever in patients receiving first-line adjuvant chemotherapy for epithelial ovarian cancer. Gynecol Oncol 2006; 103:181.</a></li><li><a class="nounderline abstract_t">Herskovic A, Martz K, al-Sarraf M, et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med 1992; 326:1593.</a></li><li><a class="nounderline abstract_t">Pignon JP, Arriagada R, Ihde DC, et al. A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med 1992; 327:1618.</a></li><li><a class="nounderline abstract_t">Bunn PA Jr, Crowley J, Kelly K, et al. Chemoradiotherapy with or without granulocyte-macrophage colony-stimulating factor in the treatment of limited-stage small-cell lung cancer: a prospective phase III randomized study of the Southwest Oncology Group. J Clin Oncol 1995; 13:1632.</a></li><li><a class="nounderline abstract_t">Staar S, Rudat V, Stuetzer H, et al. Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy--results of a multicentric randomized German trial in advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 2001; 50:1161.</a></li><li><a class="nounderline abstract_t">Haim N, Shulman K, Goldberg H, Tsalic M. The safety of full-dose chemotherapy with secondary prophylactic granulocyte colony stimulating factor (G-CSF) following a prior cycle with febrile neutropenia. Med Oncol 2005; 22:229.</a></li><li><a class="nounderline abstract_t">Chouaid C, Bassinet L, Fuhrman C, et al. Routine use of granulocyte colony-stimulating factor is not cost-effective and does not increase patient comfort in the treatment of small-cell lung cancer: an analysis using a Markov model. J Clin Oncol 1998; 16:2700.</a></li><li><a class="nounderline abstract_t">Crawford J, Ozer H, Stoller R, et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 1991; 325:164.</a></li><li><a class="nounderline abstract_t">Debled M, Houédé N, Madranges N, et al. Does chemotherapy-induced neutropaenia result in a postponement of adjuvant or neoadjuvant regimens in breast cancer patients? Results of a retrospective analysis. Br J Cancer 2007; 97:1642.</a></li><li><a class="nounderline abstract_t">Hartmann LC, Tschetter LK, Habermann TM, et al. Granulocyte colony-stimulating factor in severe chemotherapy-induced afebrile neutropenia. N Engl J Med 1997; 336:1776.</a></li><li><a class="nounderline abstract_t">Mhaskar R, Clark OA, Lyman G, et al. Colony-stimulating factors for chemotherapy-induced febrile neutropenia. Cochrane Database Syst Rev 2014; :CD003039.</a></li><li><a class="nounderline abstract_t">Kuderer NM, Dale DC, Crawford J, et al. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 2006; 106:2258.</a></li><li><a class="nounderline abstract_t">Beveridge RA, Miller JA, Kales AN, et al. A comparison of efficacy of sargramostim (yeast-derived RhuGM-CSF) and filgrastim (bacteria-derived RhuG-CSF) in the therapeutic setting of chemotherapy-induced myelosuppression. Cancer Invest 1998; 16:366.</a></li><li><a class="nounderline abstract_t">Stull DM, Bilmes R, Kim H, Fichtl R. Comparison of sargramostim and filgrastim in the treatment of chemotherapy-induced neutropenia. Am J Health Syst Pharm 2005; 62:83.</a></li><li><a class="nounderline abstract_t">Wong SF, Chan HO. Effects of a formulary change from granulocyte colony-stimulating factor to granulocyte-macrophage colony-stimulating factor on outcomes in patients treated with myelosuppressive chemotherapy. Pharmacotherapy 2005; 25:372.</a></li><li><a class="nounderline abstract_t">Milkovich G, Moleski RJ, Reitan JF, et al. Comparative safety of filgrastim versus sargramostim in patients receiving myelosuppressive chemotherapy. Pharmacotherapy 2000; 20:1432.</a></li><li><a class="nounderline abstract_t">Heaney ML, Toy EL, Vekeman F, et al. Comparison of hospitalization risk and associated costs among patients receiving sargramostim, filgrastim, and pegfilgrastim for chemotherapy-induced neutropenia. Cancer 2009; 115:4839.</a></li><li><a class="nounderline abstract_t">Weycker D, Malin J, Barron R, et al. Comparative effectiveness of filgrastim, pegfilgrastim, and sargramostim as prophylaxis against hospitalization for neutropenic complications in patients with cancer receiving chemotherapy. Am J Clin Oncol 2012; 35:267.</a></li><li class="breakAll">NCCN guidelines for supportive care available online at https://www.nccn.org/professionals/physician_gls/#supportive (Accessed on June 16, 2020).</li><li><a class="nounderline abstract_t">Clemons M, Fergusson D, Simos D, et al. A multicentre, randomised trial comparing schedules of G-CSF (filgrastim) administration for primary prophylaxis of chemotherapy-induced febrile neutropenia in early stage breast cancer. Ann Oncol 2020; 31:951.</a></li><li><a class="nounderline abstract_t">Papaldo P, Lopez M, Marolla P, et al. Impact of five prophylactic filgrastim schedules on hematologic toxicity in early breast cancer patients treated with epirubicin and cyclophosphamide. J Clin Oncol 2005; 23:6908.</a></li><li><a class="nounderline abstract_t">Skarlos DV, Timotheadou E, Galani E, et al. Pegfilgrastim administered on the same day with dose-dense adjuvant chemotherapy for breast cancer is associated with a higher incidence of febrile neutropenia as compared to conventional growth factor support: matched case-control study of the Hellenic Cooperative Oncology Group. Oncology 2009; 77:107.</a></li><li><a class="nounderline abstract_t">Spunt SL, Irving H, Frost J, et al. Phase II, randomized, open-label study of pegfilgrastim-supported VDC/IE chemotherapy in pediatric sarcoma patients. J Clin Oncol 2010; 28:1329.</a></li><li><a class="nounderline abstract_t">Lyman GH, Allcott K, Garcia J, et al. The effectiveness and safety of same-day versus next-day administration of long-acting granulocyte colony-stimulating factors for the prophylaxis of chemotherapy-induced neutropenia: a systematic review. Support Care Cancer 2017; 25:2619.</a></li><li><a class="nounderline abstract_t">Green MD, Koelbl H, Baselga J, et al. A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol 2003; 14:29.</a></li><li><a class="nounderline abstract_t">Holmes FA, O'Shaughnessy JA, Vukelja S, et al. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. J Clin Oncol 2002; 20:727.</a></li><li><a class="nounderline abstract_t">Vose JM, Crump M, Lazarus H, et al. Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma. J Clin Oncol 2003; 21:514.</a></li><li><a class="nounderline abstract_t">Fox E, Widemann BC, Hawkins DS, et al. Randomized trial and pharmacokinetic study of pegfilgrastim versus filgrastim after dose-intensive chemotherapy in young adults and children with sarcomas. Clin Cancer Res 2009; 15:7361.</a></li><li><a class="nounderline abstract_t">Shi YK, Chen Q, Zhu YZ, et al. Pegylated filgrastim is comparable with filgrastim as support for commonly used chemotherapy regimens: a multicenter, randomized, crossover phase 3 study. Anticancer Drugs 2013; 24:641.</a></li><li><a class="nounderline abstract_t">Pfeil AM, Allcott K, Pettengell R, et al. Efficacy, effectiveness and safety of long-acting granulocyte colony-stimulating factors for prophylaxis of chemotherapy-induced neutropenia in patients with cancer: a systematic review. Support Care Cancer 2015; 23:525.</a></li><li><a class="nounderline abstract_t">Bondarenko I, Gladkov OA, Elsaesser R, et al. Efficacy and safety of lipegfilgrastim versus pegfilgrastim: a randomized, multicenter, active-control phase 3 trial in patients with breast cancer receiving doxorubicin/docetaxel chemotherapy. BMC Cancer 2013; 13:386.</a></li><li><a class="nounderline abstract_t">Lee KH, Kim JY, Lee MH, et al. A randomized, multicenter, phase II/III study to determine the optimal dose and to evaluate the efficacy and safety of pegteograstim (GCPGC) on chemotherapy-induced neutropenia compared to pegfilgrastim in breast cancer patients: KCSG PC10-09. Support Care Cancer 2016; 24:1709.</a></li><li><a class="nounderline abstract_t">Cornes P, Gascon P, Chan S, et al. Systematic Review and Meta-analysis of Short- versus Long-Acting Granulocyte Colony-Stimulating Factors for Reduction of Chemotherapy-Induced Febrile Neutropenia. Adv Ther 2018; 35:1816.</a></li><li class="breakAll">RYZNEUTA (efbemalenograstim alfa-vuxw) injection, for
subcutaneous use. US Prescribing Information. US Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761134s000lbl.pdf (Accessed on November 28, 2023).</li><li><a class="nounderline abstract_t">Shin KH, Kim TE, Lim KS, et al. Pharmacokinetic and pharmacodynamic properties of a new long-acting granulocyte colony-stimulating factor (HM10460A) in healthy volunteers. BioDrugs 2013; 27:149.</a></li><li><a class="nounderline abstract_t">Barrett JA, Choi J, Lakshmikanthan S, et al. Eflapegrastim's enhancement of efficacy compared with pegfilgrastim in neutropenic rats supports potential for same-day dosing. Exp Hematol 2020; 92:51.</a></li><li><a class="nounderline abstract_t">Schwartzberg LS, Bhat G, Peguero J, et al. Eflapegrastim, a Long-Acting Granulocyte-Colony Stimulating Factor for the Management of Chemotherapy-Induced Neutropenia: Results of a Phase III Trial. Oncologist 2020; 25:e1233.</a></li><li><a class="nounderline abstract_t">Cobb PW, Moon YW, Mezei K, et al. A comparison of eflapegrastim to pegfilgrastim in the management of chemotherapy-induced neutropenia in patients with early-stage breast cancer undergoing cytotoxic chemotherapy (RECOVER): A Phase 3 study. Cancer Med 2020; 9:6234.</a></li><li class="breakAll">Schwartzberg LS, Bhat G, Resstrepo A, et al. PS9-59. Pooled efficacy analysis from two phase 3 studies in patients receiving eflapegrastim, a novel, long-acting granulocyte-colony stimulating factor, following TC for early-stage breast cancer (abstract). Data presented at the annual San Antonio Breast Cancer Symposium, December 2020, San Antonio, Tx. Abstract avaiable online at https://www.abstractsonline.com/pp8/#!/9223/presentation/1323. (Accessed on September 15, 2022).</li><li class="breakAll">Corrected BLA approval. US Food and Drug Administration. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2022/761148Orig1s000Corrected_ltr.pdf (Accessed on September 19, 2022).</li><li><a class="nounderline abstract_t">Lyman GH, Yau L, Nakov R, Krendyukov A. Overall survival and risk of second malignancies with cancer chemotherapy and G-CSF support. Ann Oncol 2018; 29:1903.</a></li><li><a class="nounderline abstract_t">Jabagi MJ, Vey N, Goncalves A, et al. Risk of secondary hematologic malignancies associated with breast cancer chemotherapy and G-CSF support: A nationwide population-based cohort. Int J Cancer 2021; 148:375.</a></li><li><a class="nounderline abstract_t">Jabagi MJ, Goncalves A, Vey N, et al. Risk of Hematologic Malignant Neoplasms after Postoperative Treatment of Breast Cancer. Cancers (Basel) 2019; 11.</a></li><li class="breakAll">GRANIX (tbo-filgrastim) injection, for subcutaneous use. US Prescribing Information. US Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125294s058lbl.pdf (Accessed on November 28, 2023).</li><li class="breakAll">Neupogen (filgrastim) for Injection. Supplemental biologics license application. US Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2021/103353orig1s5196ltr.pdf (Accessed on January 12, 2021).</li><li class="breakAll">Neulasta (pegfilgrastim) for Injection. Supplemental biologics license application. US Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2021/125031Orig1s202ltr.pdf (Accessed on January 12, 2021).</li></ol></div><div id="topicVersionRevision">Topic 16889 Version 61.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15751024" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20715160" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Risk of mortality in patients with cancer who experience febrile neutropenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21258094" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26169616" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26169616" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27664247" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Management of febrile neutropaenia: ESMO Clinical Practice Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27664247" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Management of febrile neutropaenia: ESMO Clinical Practice Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11032599" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16682725" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Cost-effectiveness of adding granulocyte colony-stimulating factor to primary prophylaxis with antibiotics in small-cell lung cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15718314" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20029970" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Evaluation of direct medical costs of hospitalization for febrile neutropenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26712901" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Interpreting febrile neutropenia rates from randomized, controlled trials for consideration of primary prophylaxis in the real world: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17634496" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17876022" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Meta-analysis: effect of prophylactic hematopoietic colony-stimulating factors on mortality and outcomes of infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21943360" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18843642" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25821144" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : The impact of primary prophylaxis with granulocyte colony-stimulating factors on febrile neutropenia during chemotherapy: a systematic review and meta-analysis of randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23514290" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Colony-stimulating factors for febrile neutropenia during cancer therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23788754" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : The impact of the granulocyte colony-stimulating factor on chemotherapy dose intensity and cancer survival: a systematic review and meta-analysis of randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9187068" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Human granulocyte colony-stimulating factor after induction chemotherapy in children with acute lymphoblastic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16258098" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: a Dutch Randomized Phase III Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16766587" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17846019" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Pegfilgrastim +/- ciprofloxacin for primary prophylaxis with TAC (docetaxel/doxorubicin/cyclophosphamide) chemotherapy for breast cancer. Results from the GEPARTRIO study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23630211" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Primary granulocyte colony-stimulating factor prophylaxis during the first two cycles only or throughout all chemotherapy cycles in patients with breast cancer at risk for febrile neutropenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26285243" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Importance of Risk Factors for Febrile Neutropenia Among Patients Receiving Chemotherapy Regimens Not Classified as High-Risk in Guidelines for Myeloid Growth Factor Use.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1381626" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12872339" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Targeted filgrastim support in patients with early-stage breast carcinoma: toward the implementation of a risk model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9469362" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy. European Organization for Research and Treatment of Cancer, Genito-Urinary Group, and the Medical Research Council Testicular Cancer Working Party, Cambridge, United Kingdom.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19748281" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Pegfilgrastim primary prophylaxis vs. current practice neutropenia management in elderly breast cancer patients receiving chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11762805" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Reduction of chemotherapy-induced febrile leucopenia by prophylactic use of ciprofloxacin and roxithromycin in small-cell lung cancer patients: an EORTC double-blind placebo-controlled phase III study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18845996" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Identifying patients at high risk for neutropenic complications during chemotherapy for metastatic breast cancer with doxorubicin or pegylated liposomal doxorubicin: the development of a prediction model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21509769" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Predicting individual risk of neutropenic complications in patients receiving cancer chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19139177" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : A general chemotherapy myelotoxicity score to predict febrile neutropenia in hematological malignancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16574203" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Characterization of neutropenic fever in patients receiving first-line adjuvant chemotherapy for epithelial ovarian cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1584260" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1331787" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : A meta-analysis of thoracic radiotherapy for small-cell lung cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7602352" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Chemoradiotherapy with or without granulocyte-macrophage colony-stimulating factor in the treatment of limited-stage small-cell lung cancer: a prospective phase III randomized study of the Southwest Oncology Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11483325" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy--results of a multicentric randomized German trial in advanced head-and-neck cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16110133" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : The safety of full-dose chemotherapy with secondary prophylactic granulocyte colony stimulating factor (G-CSF) following a prior cycle with febrile neutropenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9704720" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Routine use of granulocyte colony-stimulating factor is not cost-effective and does not increase patient comfort in the treatment of small-cell lung cancer: an analysis using a Markov model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1711156" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18000502" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Does chemotherapy-induced neutropaenia result in a postponement of adjuvant or neoadjuvant regimens in breast cancer patients? Results of a retrospective analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9187067" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Granulocyte colony-stimulating factor in severe chemotherapy-induced afebrile neutropenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25356786" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Colony-stimulating factors for chemotherapy-induced febrile neutropenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16575919" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9679526" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : A comparison of efficacy of sargramostim (yeast-derived RhuGM-CSF) and filgrastim (bacteria-derived RhuG-CSF) in the therapeutic setting of chemotherapy-induced myelosuppression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15658078" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Comparison of sargramostim and filgrastim in the treatment of chemotherapy-induced neutropenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15843284" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Effects of a formulary change from granulocyte colony-stimulating factor to granulocyte-macrophage colony-stimulating factor on outcomes in patients treated with myelosuppressive chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11130215" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Comparative safety of filgrastim versus sargramostim in patients receiving myelosuppressive chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19637341" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Comparison of hospitalization risk and associated costs among patients receiving sargramostim, filgrastim, and pegfilgrastim for chemotherapy-induced neutropenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21378538" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Comparative effectiveness of filgrastim, pegfilgrastim, and sargramostim as prophylaxis against hospitalization for neutropenic complications in patients with cancer receiving chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21378538" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Comparative effectiveness of filgrastim, pegfilgrastim, and sargramostim as prophylaxis against hospitalization for neutropenic complications in patients with cancer receiving chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32325257" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : A multicentre, randomised trial comparing schedules of G-CSF (filgrastim) administration for primary prophylaxis of chemotherapy-induced febrile neutropenia in early stage breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16129844" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Impact of five prophylactic filgrastim schedules on hematologic toxicity in early breast cancer patients treated with epirubicin and cyclophosphamide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19622901" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Pegfilgrastim administered on the same day with dose-dense adjuvant chemotherapy for breast cancer is associated with a higher incidence of febrile neutropenia as compared to conventional growth factor support: matched case-control study of the Hellenic Cooperative Oncology Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20142595" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Phase II, randomized, open-label study of pegfilgrastim-supported VDC/IE chemotherapy in pediatric sarcoma patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28484882" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : The effectiveness and safety of same-day versus next-day administration of long-acting granulocyte colony-stimulating factors for the prophylaxis of chemotherapy-induced neutropenia: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12488289" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11821454" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12560443" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19920107" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Randomized trial and pharmacokinetic study of pegfilgrastim versus filgrastim after dose-intensive chemotherapy in young adults and children with sarcomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23571496" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Pegylated filgrastim is comparable with filgrastim as support for commonly used chemotherapy regimens: a multicenter, randomized, crossover phase 3 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25284721" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Efficacy, effectiveness and safety of long-acting granulocyte colony-stimulating factors for prophylaxis of chemotherapy-induced neutropenia in patients with cancer: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23945072" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Efficacy and safety of lipegfilgrastim versus pegfilgrastim: a randomized, multicenter, active-control phase 3 trial in patients with breast cancer receiving doxorubicin/docetaxel chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26423618" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : A randomized, multicenter, phase II/III study to determine the optimal dose and to evaluate the efficacy and safety of pegteograstim (GCPGC) on chemotherapy-induced neutropenia compared to pegfilgrastim in breast cancer patients: KCSG PC10-09.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30298233" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Systematic Review and Meta-analysis of Short- versus Long-Acting Granulocyte Colony-Stimulating Factors for Reduction of Chemotherapy-Induced Febrile Neutropenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30298233" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Systematic Review and Meta-analysis of Short- versus Long-Acting Granulocyte Colony-Stimulating Factors for Reduction of Chemotherapy-Induced Febrile Neutropenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23359067" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Pharmacokinetic and pharmacodynamic properties of a new long-acting granulocyte colony-stimulating factor (HM10460A) in healthy volunteers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33002567" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Eflapegrastim's enhancement of efficacy compared with pegfilgrastim in neutropenic rats supports potential for same-day dosing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32476162" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Eflapegrastim, a Long-Acting Granulocyte-Colony Stimulating Factor for the Management of Chemotherapy-Induced Neutropenia: Results of a Phase III Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32687266" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : A comparison of eflapegrastim to pegfilgrastim in the management of chemotherapy-induced neutropenia in patients with early-stage breast cancer undergoing cytotoxic chemotherapy (RECOVER): A Phase 3 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32687266" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : A comparison of eflapegrastim to pegfilgrastim in the management of chemotherapy-induced neutropenia in patients with early-stage breast cancer undergoing cytotoxic chemotherapy (RECOVER): A Phase 3 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32687266" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : A comparison of eflapegrastim to pegfilgrastim in the management of chemotherapy-induced neutropenia in patients with early-stage breast cancer undergoing cytotoxic chemotherapy (RECOVER): A Phase 3 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30099478" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Overall survival and risk of second malignancies with cancer chemotherapy and G-CSF support.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32683691" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Risk of secondary hematologic malignancies associated with breast cancer chemotherapy and G-CSF support: A nationwide population-based cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31569513" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Risk of Hematologic Malignant Neoplasms after Postoperative Treatment of Breast Cancer.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
